New hope for Hard-to-Treat breast cancer: drug trial targets advanced TNBC
Disease control
Recruiting now
This study tests a new drug called tenalisib in 40 people with metastatic triple negative breast cancer (TNBC) who have already tried 1 to 3 other treatments. The goal is to see if tenalisib can shrink tumors or stop them from growing for at least 16 weeks. Researchers will also …
Phase: PHASE2 • Sponsor: Rhizen Pharmaceuticals SA • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC